

Resource Summary Report

Generated by [NIF](#) on Jul 29, 2026

Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43

RRID:AB_394284

Type: Antibody

Proper Citation

BD Biosciences Cat# 551892, RRID:AB_394284

Antibody Information

URL: http://antibodyregistry.org/AB_394284

Proper Citation: BD Biosciences Cat# 551892, RRID:AB_394284

Target Antigen: CD279 (PD-1)

Host Organism: armenian hamster

Clonality: monoclonal

Comments: Applications: Flow cytometry

Antibody Name: Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43

Description: This monoclonal targets CD279 (PD-1)

Target Organism: mouse

Clone ID: J43

Antibody ID: AB_394284

Vendor: BD Biosciences

Catalog Number: 551892

Record Creation Time: 20250820T052424+0000

Record Last Update: 20250820T212953+0000

Ratings and Alerts

No rating or validation information has been found for Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43.

No alerts have been found for Armenian Hamster Anti-CD279 Monoclonal Antibody, Phycoerythrin Conjugated, Clone J43.

Data and Source Information

Source: [Antibody Registry](#)

Usage and Citation Metrics

We found 15 mentions in open access literature.

Listed below are recent publications. The full list is available at [NIF](#) .

Cao C, et al. (2024) CXCR4 orchestrates the TOX-programmed exhausted phenotype of CD8+ T cells via JAK2/STAT3 pathway. *Cell genomics*, 4(10), 100659.

He C, et al. (2024) UFL1 ablation in T cells suppresses PD-1 UFMylation to enhance anti-tumor immunity. *Molecular cell*, 84(6), 1120.

Yang C, et al. (2024) Targeting the immune privilege of tumor-initiating cells to enhance cancer immunotherapy. *Cancer cell*, 42(12), 2064.

Li X, et al. (2024) Deficiency of CBL and CBLB ubiquitin ligases leads to hyper T follicular helper cell responses and lupus by reducing BCL6 degradation. *Immunity*, 57(7), 1603.

Tesfay MZ, et al. (2024) Enhancing immune response and survival in hepatocellular carcinoma with novel oncolytic Jurona virus and immune checkpoint blockade. *Molecular therapy. Oncology*, 32(4), 200913.

Xiao X, et al. (2023) ERK and USP5 govern PD-1 homeostasis via deubiquitination to modulate tumor immunotherapy. *Nature communications*, 14(1), 2859.

Dan J, et al. (2023) Oncolytic virus M1 functions as a bifunctional checkpoint inhibitor to enhance the antitumor activity of DC vaccine. *Cell reports. Medicine*, 4(10), 101229.

Ertveldt T, et al. (2023) Targeted α -Therapy Using ^{225}Ac Radiolabeled Single-Domain Antibodies Induces Antigen-Specific Immune Responses and Instills Immunomodulation Both Systemically and at the Tumor Microenvironment. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*, 64(5), 751.

Masle-Farquhar E, et al. (2022) STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation. *Immunity*, 55(12), 2386.

Wan S, et al. (2021) Costimulation molecules differentially regulate the ERK-Zfp831 axis to shape T follicular helper cell differentiation. *Immunity*, 54(12), 2740.

Sun L, et al. (2021) Transcription factor Ascl2 promotes germinal center B cell responses by directly regulating AID transcription. *Cell reports*, 35(9), 109188.

Du H, et al. (2019) Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. *Cancer cell*, 35(2), 221.

Shen E, et al. (2019) Control of Germinal Center Localization and Lineage Stability of Follicular Regulatory T Cells by the Blimp1 Transcription Factor. *Cell reports*, 29(7), 1848.

Ma X, et al. (2019) Cholesterol Induces CD8+ T Cell Exhaustion in the Tumor Microenvironment. *Cell metabolism*, 30(1), 143.

Stutz MD, et al. (2018) Is Receptor-Interacting Protein Kinase 3 a Viable Therapeutic Target for *Mycobacterium tuberculosis* Infection? *Frontiers in immunology*, 9, 1178.